Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors

This study is being done to answer the following question:
Which standard therapy is better for controlling your cancer for a longer period of time?
We are doing this study because we want to find out which approach is better or worse for your
advanced pancreatic neuroendocrine cancer. The usual approach is defined as care most
people get for advanced pancreatic neuroendocrine cancer.